Zhang X - Search Results

1

RBD-mRNA vaccine induces broadly neutralizing antibodies against Omicron and multiple other variants and protects mice from SARS-CoV-2 challenge.

Shi J, Zheng J, Zhang X, Tai W, Odle AE, Perlman S, Du L. Shi J, et al. Among authors: zhang x. Transl Res. 2022 Oct;248:11-21. doi: 10.1016/j.trsl.2022.04.007. Epub 2022 Apr 28. Transl Res. 2022. PMID: 35489692 Free PMC article.

2

Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.

Du L, Zhao G, Zhang X, Liu Z, Yu H, Zheng BJ, Zhou Y, Jiang S. Du L, et al. Among authors: zhang x. Biochem Biophys Res Commun. 2010 Jul 2;397(3):580-5. doi: 10.1016/j.bbrc.2010.05.161. Biochem Biophys Res Commun. 2010. PMID: 20617558 Free PMC article.

3

A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.

Du L, Leung VH, Zhang X, Zhou J, Chen M, He W, Zhang HY, Chan CC, Poon VK, Zhao G, Sun S, Cai L, Zhou Y, Zheng BJ, Jiang S. Du L, et al. Among authors: zhang x, zhang hy. PLoS One. 2011 Jan 27;6(1):e16555. doi: 10.1371/journal.pone.0016555. PLoS One. 2011. PMID: 21304591 Free PMC article.

4

Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection.

Du L, Zhang X, Liu J, Jiang S. Du L, et al. Among authors: zhang x. J Vis Exp. 2011 May 2;(51):2444. doi: 10.3791/2444. J Vis Exp. 2011. PMID: 21587153 Free PMC article.

5

A critical HA1 neutralizing domain of H5N1 influenza in an optimal conformation induces strong cross-protection.

Du L, Zhao G, Sun S, Zhang X, Zhou X, Guo Y, Li Y, Zhou Y, Jiang S. Du L, et al. Among authors: zhang x. PLoS One. 2013;8(1):e53568. doi: 10.1371/journal.pone.0053568. Epub 2013 Jan 8. PLoS One. 2013. PMID: 23320093 Free PMC article.

6

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L. Tai W, et al. Among authors: zhang x. Cell Mol Immunol. 2020 Jun;17(6):613-620. doi: 10.1038/s41423-020-0400-4. Epub 2020 Mar 19. Cell Mol Immunol. 2020. PMID: 32203189 Free PMC article.

7

Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2.

Tai W, Zhang X, He Y, Jiang S, Du L. Tai W, et al. Among authors: zhang x. Antiviral Res. 2020 Jul;179:104820. doi: 10.1016/j.antiviral.2020.104820. Epub 2020 May 13. Antiviral Res. 2020. PMID: 32405117 Free PMC article.

8

A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2.

Tai W, Zhang X, Drelich A, Shi J, Hsu JC, Luchsinger L, Hillyer CD, Tseng CK, Jiang S, Du L. Tai W, et al. Among authors: zhang x. Cell Res. 2020 Oct;30(10):932-935. doi: 10.1038/s41422-020-0387-5. Epub 2020 Aug 5. Cell Res. 2020. PMID: 32759966 Free PMC article. No abstract available.

9

Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2.

Jiang S, Zhang X, Du L. Jiang S, et al. Among authors: zhang x. Expert Opin Ther Targets. 2021 Jun;25(6):415-421. doi: 10.1080/14728222.2020.1820482. Epub 2020 Sep 17. Expert Opin Ther Targets. 2021. PMID: 32941780 Free PMC article. No abstract available.

10

Neutralizing antibodies for the treatment of COVID-19.

Jiang S, Zhang X, Yang Y, Hotez PJ, Du L. Jiang S, et al. Among authors: zhang x. Nat Biomed Eng. 2020 Dec;4(12):1134-1139. doi: 10.1038/s41551-020-00660-2. Nat Biomed Eng. 2020. PMID: 33293725 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

179,040 results

Search Page

Filters